Satsuma Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- . (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, will present a corporate update at the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020 in New York City.
| 9th Annual SVB Leerink Global Healthcare Conference | ||
| Date: | Tuesday, February 25th, 2020 | |
| Time: | 11:30am Eastern Time | |
| Location: | Lotte New York Palace Hotel, The Apartment Room, 4th Floor | |
| Webcast: | ||
A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at . The webcast replay will be available approximately two hours after the presentation ends and will be accessible for 90 days.
About Satsuma Pharmaceuticals and STS101
Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product for the acute treatment of migraine, STS101. STS101 is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate (DHE), which can be quickly and easily self-administered with a proprietary pre-filled, single-use, nasal delivery device. In developing STS101, Satsuma has applied proprietary nasal drug delivery, dry-powder formulation, and engineered drug particle technologies to create a compact, simple-to-use, non-injectable DHE product that can be rapidly self-administered in a matter of seconds. The Company believes STS101 would, if approved, be an attractive migraine treatment option for many patients and may enable a larger number of people with migraine to realize the long-recognized therapeutic benefits of DHE therapy. STS101 has undergone extensive pre-clinical development, completed a Phase 1 clinical trial, and is currently in Phase 3 development.
Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit .
INVESTOR AND CORPORATE CONTACTS:
Corey Davis, PhD
LifeSci Advisors, LLC
Tom O’Neil, Chief Financial Officer
Satsuma Pharmaceuticals, Inc.
